Mcrae Capital Management Inc. Sells 515 Shares of Johnson & Johnson $JNJ

Mcrae Capital Management Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 12,548 shares of the company’s stock after selling 515 shares during the period. Mcrae Capital Management Inc.’s holdings in Johnson & Johnson were worth $1,917,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. GFG Capital LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the first quarter worth about $52,000. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on JNJ. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Trading Up 0.5%

JNJ opened at $186.92 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company’s 50 day moving average price is $184.06 and its two-hundred day moving average price is $168.42. The firm has a market capitalization of $450.33 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.